The Alzheimer's Disease Neuroimaging Initiative (ADNI) is the largest and most comprehensive Alzheimer's research effort in the United States. It is helping to identify the earliest signs of the disease, when brain damage begins and when treatments offer the greatest promise for slowing down its progression. However, the study's progress is being slowed by recruitment challenges.
ADNI is designed to validate the use of biomarkers including blood tests, tests of cerebrospinal fluid, and MRI/PET imaging for Alzheimer's disease clinical trials and diagnosis. Researchers are looking specifically for people with diagnosed late-mild cognitive impairment and Alzheimer's disease to continue their work in 55 clinical sites across the nation.
For more information, visit www.adni-info.org.